Antimicrobial surveillance: A 20-year history of the SMART approach to addressing global antimicrobial resistance into the future

• Published in: International journal of antimicrobial agents 2023-12, Vol.62 (6), p.107014-107014, Article 107014
• Main Authors: Cantón, Rafael, Gottlieb, Thomas, Coombs, Geoffrey W., Woo, Patrick C.Y., Korman, Tony M., Garcia-Castillo, Maria, Daley, Denise, Bauer, Karri A., Wong, Michael, Wolf, Dominik J., Siddiqui, Fakhar, Motyl, Mary
• Format: Article
• Language: English
• Subjects: Antibacterial agents; antibiotic resistance; Antimicrobial resistance; Epidemiology; Global; Gram-negative pathogens; health services; monitoring; mortality; pharmaceutical industry; public health
• ISSN: 0924-8579; 1872-7913
• DOI: 10.1016/j.ijantimicag.2023.107014

•Antimicrobial resistance (AMR) threatens public health worldwide.•Comprehensive surveillance programmes are essential to combatting AMR.•SMART is a long-running, robust, global surveillance programme.•Data are also collected from resource-limited countries especially impacted by AMR.•SMART data can inform treatment guidelines and clinical decision-making. Antimicrobial resistance (AMR) is a major global public health threat, particularly affecting patients in resource-poor settings. Comprehensive surveillance programmes are essential to reducing the high mortality and morbidity associated with AMR and are integral to informing treatment decisions and guidelines, appraising the effectiveness of intervention strategies, and directing development of new antibacterial agents. Various surveillance programmes exist worldwide, including those administered by government bodies or funded by the pharmaceutical industry. One of the largest and longest running industry-sponsored AMR surveillance programme is the Study for Monitoring Antimicrobial Resistance Trends (SMART), which recently completed its 20th year. The SMART database has grown to almost 500 000 isolates from over 200 sites in more than 60 countries, encompassing all major geographic regions and including many sites in low- and middle-income countries. The SMART surveillance programme has evolved in scope over time, including additional antibacterial agents, pathogens and infection sites, in line with changing epidemiology and medical need. Surveillance data from SMART and similar programmes have been used successfully to detect emerging resistance threats and AMR patterns in specific countries and regions, thus informing national and local clinical treatment guidelines. The SMART database can be accessed readily by physicians and researchers globally, which may be especially valuable to those from countries with limited healthcare resources, where surveillance and resistance data are rarely collected. Continued participation from as many sites as possible worldwide and maintenance of adequate funding are critical factors to fully realising the potential of large-scale AMR surveillance programmes into the future.